These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 9357391)

  • 41. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity.
    Ducharme J; Abdullah S; Wainer IW
    J Chromatogr B Biomed Appl; 1996 Mar; 678(1):113-28. PubMed ID: 8861661
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of CYP2D6 deletion, multiplication, -1584C-->G, 31G-->A and 2988G-->a gene polymorphisms on dextromethorphan metabolism among Mexican tepehuanos and mestizos.
    Sosa-Macías M; Dorado P; Alanis-Bañuelos RE; Llerena A; Lares-Asseff I
    Pharmacology; 2010; 86(1):30-6. PubMed ID: 20588073
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.
    Funck-Brentano C; Boëlle PY; Verstuyft C; Bornert C; Becquemont L; Poirier JM
    Eur J Clin Pharmacol; 2005 Dec; 61(11):821-9. PubMed ID: 16315033
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans.
    Gaedigk A; Bradford LD; Marcucci KA; Leeder JS
    Clin Pharmacol Ther; 2002 Jul; 72(1):76-89. PubMed ID: 12152006
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test.
    Eap CB; Bondolfi G; Zullino D; Bryois C; Fuciec M; Savary L; Jonzier-Perey M; Baumann P
    Ther Drug Monit; 2001 Jun; 23(3):228-31. PubMed ID: 11360030
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CYP2D6 mRNA expression in circulating peripheral blood mononuclear cells correlates with in vivo debrisoquine hydroxylase activity in extensive metabolizers.
    Carcillo JA; Parise RA; Adedoyin A; Frye R; Branch RA; Romkes M
    Res Commun Mol Pathol Pharmacol; 1996 Feb; 91(2):149-159. PubMed ID: 8832907
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.
    McCune JS; Lindley C; Decker JL; Williamson KM; Meadowcroft AM; Graff D; Sawyer WT; Blough DK; Pieper JA
    J Clin Pharmacol; 2001 Jul; 41(7):723-31. PubMed ID: 11452704
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions.
    Storelli F; Matthey A; Lenglet S; Thomas A; Desmeules J; Daali Y
    Clin Pharmacol Ther; 2018 Jul; 104(1):148-157. PubMed ID: 28940476
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A sensitive LC-MS/MS assay for the determination of dextromethorphan and metabolites in human urine--application for drug interaction studies assessing potential CYP3A and CYP2D6 inhibition.
    Vengurlekar SS; Heitkamp J; McCush F; Velagaleti PR; Brisson JH; Bramer SL
    J Pharm Biomed Anal; 2002 Aug; 30(1):113-24. PubMed ID: 12151071
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan.
    Basci NE; Bozkurt A; Kayaalp SO; Sayal A; Isimer A
    Eur J Drug Metab Pharmacokinet; 1998; 23(1):1-5. PubMed ID: 9625265
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CYP2D6 polymorphism in a Mexican American population.
    Mendoza R; Wan YJ; Poland RE; Smith M; Zheng Y; Berman N; Lin KM
    Clin Pharmacol Ther; 2001 Dec; 70(6):552-60. PubMed ID: 11753272
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.
    Kashuba AD; Nafziger AN; Kearns GL; Leeder JS; Gotschall R; Rocci ML; Kulawy RW; Beck DJ; Bertino JS
    Clin Pharmacol Ther; 1998 Sep; 64(3):257-68. PubMed ID: 9757149
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers.
    Hägg S; Spigset O; Dahlqvist R
    Br J Clin Pharmacol; 2001 Feb; 51(2):169-73. PubMed ID: 11259990
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intra-individual variability and influence of urine collection period on dextromethorphan metabolic ratios in healthy subjects.
    Chládek J; Zimová G; Martínková J; Tůma I
    Fundam Clin Pharmacol; 1999; 13(4):508-15. PubMed ID: 10456294
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytochromes in psychopharmacology.
    von Moltke LL; Greenblatt DJ; Harmatz JS; Shader RI
    J Clin Psychopharmacol; 1994 Feb; 14(1):1-4. PubMed ID: 8150999
    [No Abstract]   [Full Text] [Related]  

  • 56. Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study.
    Zawertailo LA; Kaplan HL; Busto UE; Tyndale RF; Sellers EM
    J Clin Psychopharmacol; 1998 Aug; 18(4):332-7. PubMed ID: 9690700
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication.
    Köhler D; Härtter S; Fuchs K; Sieghart W; Hiemke C
    Pharmacogenetics; 1997 Dec; 7(6):453-61. PubMed ID: 9429230
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers.
    Min DI; Ku YM; Vichiendilokkul A; Fleckenstein LL
    Pharmacotherapy; 1999 Jun; 19(6):753-9. PubMed ID: 10391422
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans.
    Jacqz-Aigrain E; Funck-Brentano C; Cresteil T
    Pharmacogenetics; 1993 Aug; 3(4):197-204. PubMed ID: 8220439
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.
    Schadel M; Wu D; Otton SV; Kalow W; Sellers EM
    J Clin Psychopharmacol; 1995 Aug; 15(4):263-9. PubMed ID: 7593709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.